TapewireFind a company

person · Reporting owner

Barrett Peter

Disclosed activity across 4 companies

Tapewire entity
26196
SEC CIK
0001291895

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Larimar Therapeutics, Inc.LRMR · Entity 5634DirectorMay 10, 2022May 13, 2022
Obsidian Therapeutics, Inc.OBX · Entity 4898DirectorAugust 03, 2026August 05, 2026
REVVITY, INC.RVTY · Entity 3382DirectorMay 07, 2026May 11, 2026
SYNLOGIC, INC.SYBX · Entity 7801DirectorJanuary 02, 2024January 04, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Larimar Therapeutics, Inc.

Report date May 10, 2022 · Filed May 13, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92 · Expires 2032-05-10Direct8,300 Reported balance After 2022-05-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-05-10 · Grant · Acquired 8,300 · Balance 8,300

F1: The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

Obsidian Therapeutics, Inc.

Report date August 03, 2026 · Filed August 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2036-08-02Direct37,653 Reported balance After 2026-08-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-08-03 · Grant · Acquired 37,653 · Balance 37,653

F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.

REVVITY, INC.

Report date May 07, 2026 · Filed May 11, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect28,293 Ending reported balance After 2026-05-07 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-05-07 · Grant · Acquired 1,015 · Balance 27,028

F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

Row 2 · 2026-05-07 · Grant · Acquired 1,265 · Balance 28,293

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

SYNLOGIC, INC.

Report date January 02, 2024 · Filed January 04, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 · Expires 2034-01-02Direct24,923 Reported balance After 2024-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-01-02 · Grant · Acquired 24,923 · Balance 24,923

F1: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and committee cash retainers of $81,500 in the aggregate. Such options vest in four equal quarterly installments on the last day of each calendar quarter during 2024 provided the Reporting Person continues to provide services to the Issuer.

F2: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and committee cash retainers of $81,500 in the aggregate. Such options vest in four equal quarterly installments on the last day of each calendar quarter during 2024 provided the Reporting Person continues to provide services to the Issuer.

F2: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 03, 2026 Filed Aug 5, 2026 20:07 UTC Obsidian Therapeutics, Inc. OBX · Entity 4898 GrantStock Option (Right to Buy) · Derivative 37,653 $0.00 Strike: $12.00 $0.00
Disclosure

SEC source: 0001193125-26-335078 · ownership.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,653

Underlying: Common Stock · 37,653 shares

Expires 2036-08-02

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Read SEC document
May 07, 2026 Filed May 11, 2026 20:05 UTC REVVITY, INC. RVTY · Entity 3382 GrantCommon Stock 1,265 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-216724 · ownership.xml · nonDerivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,293

Read SEC document
May 07, 2026 Filed May 11, 2026 20:05 UTC REVVITY, INC. RVTY · Entity 3382 GrantCommon Stock 1,015 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-216724 · ownership.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,028

F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

Read SEC document
April 30, 2025 Filed May 1, 2025 20:05 UTC REVVITY, INC. RVTY · Entity 3382 GrantCommon Stock 1,338 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-061820 · ownership.xml · nonDerivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,013

Read SEC document
April 30, 2025 Filed May 1, 2025 20:05 UTC REVVITY, INC. RVTY · Entity 3382 GrantCommon Stock 1,074 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-061820 · ownership.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,675

F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 28, 2026, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

Read SEC document
May 01, 2024 Filed May 2, 2024 20:05 UTC REVVITY, INC. RVTY · Entity 3382 GrantCommon Stock 1,218 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-052076 · ownership.xml · nonDerivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,601

Read SEC document
May 01, 2024 Filed May 2, 2024 20:05 UTC REVVITY, INC. RVTY · Entity 3382 GrantCommon Stock 977 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-052076 · ownership.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,383

F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 22, 2025, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 21:00 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 24,923 $0.00 Strike: $4.47 $0.00
Disclosure

SEC source: 0000950170-24-001821 · ownership.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,923

Underlying: Common Stock · 24,923 shares

Expires 2034-01-02

F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and committee cash retainers of $81,500 in the aggregate. Such options vest in four equal quarterly installments on the last day of each calendar quarter during 2024 provided the Reporting Person continues to provide services to the Issuer.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
June 22, 2023 Filed Jun 26, 2023 18:06 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $0.50 $0.00
Disclosure

SEC source: 0000950170-23-029787 · ownership.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-22

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
May 15, 2023 Filed May 17, 2023 20:06 UTC REVVITY, INC. RVTY · Entity 3382 GrantCommon Stock 955 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-022713 · ownership.xml · nonDerivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,406

Read SEC document
May 15, 2023 Filed May 17, 2023 20:06 UTC REVVITY, INC. RVTY · Entity 3382 GrantCommon Stock 783 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-022713 · ownership.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,451

F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 23, 2024, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control.

Read SEC document
January 03, 2023 Filed Jan 4, 2023 22:26 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 156,130 $0.00 Strike: $0.74 $0.00
Disclosure

SEC source: 0000899243-23-000663 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,130

Underlying: Common Stock · 156,130 shares

Expires 2033-01-03

F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and committee cash retainers of $81,500 in the aggregate. Such options vest in four equal quarterly installments on the last day of each calendar quarter during 2023 provided the Reporting Person continues to provide services to the Issuer.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
June 09, 2022 Filed Jun 13, 2022 20:15 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 27,000 $0.00 Strike: $1.17 $0.00
Disclosure

SEC source: 0000899243-22-022180 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
May 10, 2022 Filed May 13, 2022 00:27 UTC Larimar Therapeutics, Inc. LRMR · Entity 5634 GrantStock Option (Right to Buy) · Derivative 8,300 $0.00 Strike: $2.92 $0.00
Disclosure

SEC source: 0001062993-22-012306 · form4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2032-05-10

F1 · derivative.exercise_date: The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

Read SEC document
May 06, 2022 Filed May 9, 2022 20:05 UTC REVVITY, INC. PKI · Entity 3382 GrantCommon Stock 744 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-017245 · doc4.xml · nonDerivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,668

Read SEC document
May 06, 2022 Filed May 9, 2022 20:05 UTC REVVITY, INC. PKI · Entity 3382 GrantCommon Stock 610 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-017245 · doc4.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,924

F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 25, 2023, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 21:30 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 49,334 $0.00 Strike: $2.42 $0.00
Disclosure

SEC source: 0000899243-22-000897 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,334

Underlying: Common Stock · 49,334 shares

Expires 2032-01-03

F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and committee cash retainers of $81,500 in the aggregate. Such options vest in four equal quarterly installments on the last day of each calendar quarter during 2022 provided the Reporting Person continues to provide services to the Issuer.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
July 30, 2021 Filed Aug 2, 2021 20:05 UTC REVVITY, INC. PKI · Entity 3382 GiftCommon Stock 5,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-030974 · doc4.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,314

F1 · shares: The transaction represents a gift by the Reporting Person of 5,000 shares of common stock to a donor advised fund.

Read SEC document
June 10, 2021 Filed Jun 14, 2021 21:07 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 12,818 $0.00 Strike: $3.67 $0.00
Disclosure

SEC source: 0000899243-21-023604 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,818

Underlying: Common Stock · 12,818 shares

Expires 2031-06-10

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
May 12, 2021 Filed May 17, 2021 21:06 UTC Larimar Therapeutics, Inc. LRMR · Entity 5634 GrantStock Option (right to buy) · Derivative 8,300 $0.00 Strike: $10.34 $0.00
Disclosure

SEC source: 0001192482-21-000440 · edgar.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2031-05-12

F1 · derivative.exercise_date: The Option vests on the earlier of (a) May 12, 2022 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

Read SEC document
May 07, 2021 Filed May 10, 2021 21:35 UTC REVVITY, INC. PKI · Entity 3382 GrantCommon Stock 709 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-019008 · doc4.xml · nonDerivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,314

Read SEC document
May 07, 2021 Filed May 10, 2021 21:35 UTC REVVITY, INC. PKI · Entity 3382 GrantCommon Stock 604 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-019008 · doc4.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,605

F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 26, 2022, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control.

Read SEC document
January 04, 2021 Filed Jan 5, 2021 23:09 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 57,498 $0.00 Strike: $2.20 $0.00
Disclosure

SEC source: 0001104659-21-001076 · tm211802-1_4seq1.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,498

Underlying: Common Stock · 57,498 shares

Expires 2031-01-04

F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and audit committee cash retainers of $85,500 in the aggregate. Such options vest in four equal quarterly installments on the last day of each calendar quarter during 2021 provided the Reporting Person continues to provide services to the Issuer.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
September 29, 2020 Filed Sep 30, 2020 18:09 UTC Larimar Therapeutics, Inc. LRMR · Entity 5634 GrantStock Option (right to buy) · Derivative 16,600 $0.00 Strike: $11.90 $0.00
Disclosure

SEC source: 0001192482-20-000747 · edgar.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,600

Underlying: Common Stock · 16,600 shares

Expires 2030-07-16

F1 · derivative.exercise_date: The Option was granted on July 16, 2020 subject to stockholder approval, which was obtained at the Company's special meeting of stockholders on September 29, 2020. The vesting commencement date for the option is July 16, 2020, and the option vests in equal monthly installments over 36 months, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date.

Read SEC document
July 24, 2020 Filed Jul 29, 2020 01:19 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 1,541 $0.00 Strike: $2.23 $0.00
Disclosure

SEC source: 0000899243-20-020582 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,541

Underlying: Common Stock · 1,541 shares

Expires 2030-07-24

F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Award Plan in lieu of the non-employee director nominating and governance committee chair cash retainer of $8,000. Such options vest in four equal quarterly installments provided the Reporting Person continues to provide services to the Issuer.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
June 04, 2020 Filed Jun 8, 2020 21:30 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $2.22 $0.00
Disclosure

SEC source: 0000899243-20-015644 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
May 28, 2020 Filed May 29, 2020 20:06 UTC REVVITY, INC. PKI · Entity 3382 Exercise / conversionNQ Stock Option (right to buy) · Derivative 4,750 $0.00 Strike: $42.09 $0.00
Disclosure

SEC source: 0000899243-20-014541 · doc4.xml · derivative · entry 3

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,750 shares

Expires 2021-04-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option became exercisable in three equal annual installments beginning on April 29, 2015, which was the first anniversary of the date on which the option was granted.

Read SEC document
May 28, 2020 Filed May 29, 2020 20:06 UTC REVVITY, INC. PKI · Entity 3382 SaleCommon Stock 7,552 $100.11 $756,038.27
Disclosure

SEC source: 0000899243-20-014541 · doc4.xml · nonDerivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,001

F1 · price: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $100.10 to $100.22. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 28, 2020 Filed May 29, 2020 20:06 UTC REVVITY, INC. PKI · Entity 3382 Exercise / conversionCommon Stock 4,750 $42.09 $199,903.75
Disclosure

SEC source: 0000899243-20-014541 · doc4.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,552

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 08, 2020 Filed May 12, 2020 20:12 UTC REVVITY, INC. PKI · Entity 3382 GrantCommon Stock 1,081 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-012813 · doc4.xml · nonDerivative · entry 3

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,803

Read SEC document
May 08, 2020 Filed May 12, 2020 20:12 UTC REVVITY, INC. PKI · Entity 3382 GrantCommon Stock 298 $92.20 $27,475.60
Disclosure

SEC source: 0000899243-20-012813 · doc4.xml · nonDerivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,722

F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2021, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control.

F2 · price: Restricted stock units were awarded in lieu of the reporting person's first 2020 quarterly cash retainer payment, with the number of restricted stock units determined by dividing the amount of the cash retainer payment by the Black-Scholes value of a restricted stock unit on the date the grant was made.

Read SEC document
May 08, 2020 Filed May 12, 2020 20:12 UTC REVVITY, INC. PKI · Entity 3382 GrantCommon Stock 922 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-012813 · doc4.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,424

F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2021, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control.

Read SEC document
January 02, 2020 Filed Jul 29, 2020 01:18 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 48,656 $0.00 Strike: $2.68 $0.00
Disclosure

SEC source: 0000899243-20-020581 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,656

Underlying: Common Stock · 48,656 shares

Expires 2030-01-02

F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and audit committee cash retainers of $77,500 in the aggregate. Such options vest in four equal quarterly installments on the last day of each calendar quarter during 2020 provided the Reporting Person continues to provide services to the Issuer.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
November 11, 2019 Filed Nov 12, 2019 21:05 UTC REVVITY, INC. PKI · Entity 3382 GiftCommon Stock 955 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-027110 · doc4.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,502

F1 · shares: The transaction represents a gift by the Reporting Person of 955 shares of common stock to a donor advised fund.

Read SEC document
June 26, 2019 Filed Jun 27, 2019 23:34 UTC Larimar Therapeutics, Inc. ZFGN · Entity 5634 GrantStock Option (Right to Buy) · Derivative 27,000 $0.00 Strike: $1.25 $0.00
Disclosure

SEC source: 0000899243-19-018476 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2029-06-26

F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.

Read SEC document
June 05, 2019 Filed Jun 7, 2019 20:15 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $7.30 $0.00
Disclosure

SEC source: 0000899243-19-015996 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
April 30, 2019 Filed May 1, 2019 20:59 UTC REVVITY, INC. PKI · Entity 3382 GrantCommon Stock 1,043 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-011612 · doc4.xml · nonDerivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,457

Read SEC document
April 30, 2019 Filed May 1, 2019 20:59 UTC REVVITY, INC. PKI · Entity 3382 GrantCommon Stock 785 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-011612 · doc4.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,414

F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 30, 2020, which is the first anniversary of the date on which the grant was made.

Read SEC document
February 13, 2019 Filed Feb 14, 2019 23:26 UTC REVVITY, INC. PKI · Entity 3382 Exercise / conversionNQ Stock Option (right to buy) · Derivative 5,601 $0.00 Strike: $30.51 $0.00
Disclosure

SEC source: 0000899243-19-003704 · doc4.xml · derivative · entry 3

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,601 shares

Expires 2020-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option became exercisable in three equal annual installments beginning on April 30, 2014, which was the first anniversary of the date on which the option was granted.

Read SEC document
February 13, 2019 Filed Feb 14, 2019 23:26 UTC REVVITY, INC. PKI · Entity 3382 SaleCommon Stock 5,601 $93.62 $524,371.22
Disclosure

SEC source: 0000899243-19-003704 · doc4.xml · nonDerivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,629

F1 · price: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $93.61 to $93.64. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 13, 2019 Filed Feb 14, 2019 23:26 UTC REVVITY, INC. PKI · Entity 3382 Exercise / conversionCommon Stock 5,601 $30.51 $170,886.51
Disclosure

SEC source: 0000899243-19-003704 · doc4.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,630

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 24, 2019 Filed Jan 29, 2019 00:04 UTC Larimar Therapeutics, Inc. ZFGN · Entity 5634 GrantStock Option (Right to Buy) · Derivative 21,396 $0.00 Strike: $4.38 $0.00
Disclosure

SEC source: 0000899243-19-002067 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,396

Underlying: Common Stock · 21,396 shares

Expires 2029-01-24

F1 · derivative.exercise_date: The stock option was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Non-Qualified Stock Option Agreement and shall vest over a period of one year starting January 1, 2019 on a quarterly basis in arrears.

Read SEC document
January 02, 2019 Filed Apr 9, 2019 20:52 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 17,380 $4.39 Strike: $7.62 $76,298.20
Disclosure

SEC source: 0000899243-19-010393 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,380

Underlying: Common Stock · 17,380 shares

Expires 2029-01-02

F1 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and committee cash retainers of $76,250 in the aggregate. Such options vest in four quarterly installments on the last day of each calendar quarter during 2019 provided the Reporting Person continues to provide services to the Issuer.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
June 13, 2018 Filed Jun 14, 2018 20:05 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $9.36 $0.00
Disclosure

SEC source: 0000899243-18-016592 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2028-06-13

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to the reporting person's continued service as a director of the Corporation.

F2 · ownership.direct: The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the reporting person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Read SEC document
June 06, 2018 Filed Jun 7, 2018 21:37 UTC Larimar Therapeutics, Inc. ZFGN · Entity 5634 GrantStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $6.79 $0.00
Disclosure

SEC source: 0000899243-18-015555 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2028-06-06

F1 · derivative.exercise_date: These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 6, 2019 or the date of the 2019 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.

Read SEC document
May 03, 2018 Filed May 4, 2018 20:05 UTC REVVITY, INC. PKI · Entity 3382 GrantCommon Stock 1,386 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-011498 · doc4.xml · nonDerivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,629

Read SEC document
May 03, 2018 Filed May 4, 2018 20:05 UTC REVVITY, INC. PKI · Entity 3382 GrantCommon Stock 1,043 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-011498 · doc4.xml · nonDerivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,243

F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on May 3, 2019, which is the first anniversary of the date on which the grant was made.

Read SEC document
January 03, 2018 Filed Jan 5, 2018 22:01 UTC Larimar Therapeutics, Inc. ZFGN · Entity 5634 GrantStock Option (Right to Buy) · Derivative 17,627 $0.00 Strike: $5.18 $0.00
Disclosure

SEC source: 0000899243-18-000594 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,627

Underlying: Common Stock · 17,627 shares

Expires 2028-01-03

F1 · derivative.exercise_date: The stock option was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Non-Qualified Stock Option Agreement and shall vest over a period of one year starting January 1, 2018 on a quarterly basis in arrears.

Read SEC document
January 02, 2018 Filed Jan 3, 2018 21:31 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 11,570 $6.60 Strike: $10.80 $76,362.00
Disclosure

SEC source: 0000899243-18-000274 · doc4.xml · derivative · entry 2

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,570

Underlying: Common Stock · 11,570 shares

Expires 2028-01-02

F2 · derivative.exercise_date: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Program and 2015 Equity Incentive Award Plan in lieu of the non-employee director board and committee cash retainers of $76,250 in the aggregate. Such options vest in four quarterly installments on the last day of each calendar quarter during 2018 provided the Reporting Person continues to provide services to the Issuer.

Read SEC document
December 29, 2017 Filed Jan 3, 2018 21:31 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 17,143 $0.00 Strike: $9.70 $0.00
Disclosure

SEC source: 0000899243-18-000274 · doc4.xml · derivative · entry 1

Barrett Peter · CIK 0001291895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,143

Underlying: Common Stock · 17,143 shares

Expires 2027-12-29

F1 · derivative.exercise_date: The options vest and become exercisable in substantially equal installments on each of the first three anniversaries of August 28, 2017 subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.